Joinn Laboratories (China) (HKG:6127) said it expects to turn to profit in the first half of 2025, and report an up to 25% decrease in revenue, according to a Hong Kong bourse filing Monday.

Shares of the pharma research company fell nearly 6% in afternoon trade Tuesday.

The company expects attributable profit of 50.3 million yuan to 75.5 million yuan for the six months ended June 30, compared with a loss of 169.7 million yuan in the same period last year.

Meanwhile, the company expects to report 635.1 million yuan to 702 million yuan in revenue for the period, down 17% to 25% from the 849.4 million yuan a year prior.

Joinn Laboratories expects to post its H1 results by the end of August.